Real Money authors - Bruce Kamich

Bruce Kamich

Bruce Kamich is TheStreet's in-house technical analyst with a 43 year career with a number of bulge bracket firms like Morgan Stanley, Smith Barney Harris Upham, and Merrill Lynch. Along the way he accumulated knowledge about the fundamentals of the commodity markets, interest rates, equities and ETFs. 

In addition to writing for Kamich has been teaching technical analysis at Baruch College for the past twenty years.

Kamich was one of the earliest Chartered Market Technicians  or CMTs, a professional designation similar to the CFA title. He has authored two books on charting and technical analysis - "How Technical Analysis Works"  and "Chart Patterns." He is a two-time past president of the Market Technicians Association (now called the CMTA), the professional organization for chartists worldwide. He was also the president of the Market Technicians Association Educational Foundation (
Email Bruce Kamich

Recent Articles By The Author

Iron Mountain Is a Tough One to Climb

Here's why I'd tell traders to stand aside for now.

Western Digital's Charts Keep Going South

Here's why the outlook is still bearish for this data-tech name.

Here's How a General Mills Earnings Beat Changes Things for the Stock

We have a new price target.

HF Sinclair Is No Dinosaur: What to Expect From the Stock

Shares of the energy name are back on the upswing.

Is Lennar Worthy of a 'Down Payment' as Earnings Approach?

Let's check the charts to see if the worst is behind the homebuilder or if there is more risk ahead.

Microsoft Appears Programmed to Keep Going Down

A time to invest should arrive later, but for now MSFT looks unable to break out of a downtrend.

Let's Investigate a Way to Invest in Artificial Intelligence and Robotics

This ETF has both in its name.

My Strategy to Buy Beam Therapeutics

Let's look at the charts and indicators.

Nike's Treads Are Wearing Thin

After losing a fundamental 'supporter' let's check the charts and indicators.

Nuvalent Has Made a Base Pattern on the Charts

This biopharmaceutical firm shows promise.

Email sent

Thank you, your email to has been sent successfully.


We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight